Background: The utilization of inflammation-based scores, such as the Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), and Platelet-to-Lymphocyte Ratio (PLR), has garnered attention for their potential as prognostic indicators in various cancers. However, their predictive role in patients with intermediate-stage HCC undergoing transcatheter arterial chemoembolization (TACE) remains an area that requires further investigation, as early recognition of TACE refractoriness holds the potential to guide tailored therapeutic interventions. Methods: This multicenter international retrospective study analyzed data from patients with intermediate-stage HCC undergoing TACE between 2018 and 2024. Inflammation-based scores (NLR, LMR, PLR) were assessed preoperatively to predict treatment outcomes. Results: Two hundred and fourteen patients were enrolled. Preoperative LMR showed the largest area under the curve for the prediction of 6-months PFS, based on the ROC curve analysis. Both high LMR (≥2.24) and low NLR (<4.72) were associated with improved objective response rates and 6-month progression-free survival. Lymphocyte count emerged as a strong predictor of treatment response in both simple (p< 0.001) and multiple (p< 0.001) logistic regression analyses. Conclusions: This study highlights the prognostic value of inflammation-based scores, particularly LMR and NLR, in predicting the treatment response and short-term outcomes of patients with intermediate-stage HCC undergoing TACE. Future investigations should focus on validating these scores’ clinical applicability and assessing their impact on long-term patient survival and therapeutic decision-making.
背景：基于炎症的评分，如中性粒细胞与淋巴细胞比值（NLR）、淋巴细胞与单核细胞比值（LMR）及血小板与淋巴细胞比值（PLR），因其在多种癌症中作为预后指标的潜力而受到关注。然而，这些指标在接受经导管动脉化疗栓塞（TACE）治疗的中期肝细胞癌（HCC）患者中的预测作用仍需进一步研究，因为早期识别TACE抵抗性可能有助于指导个体化治疗干预。 方法：这项多中心国际回顾性研究分析了2018年至2024年间接受TACE治疗的中期HCC患者的数据。术前评估了基于炎症的评分（NLR、LMR、PLR）以预测治疗结果。 结果：共纳入214例患者。根据ROC曲线分析，术前LMR在预测6个月无进展生存期方面显示出最大的曲线下面积。高LMR（≥2.24）和低NLR（<4.72）均与改善的客观缓解率和6个月无进展生存期相关。在单因素（p<0.001）和多因素（p<0.001）逻辑回归分析中，淋巴细胞计数均显示出对治疗反应的强预测能力。 结论：本研究强调了基于炎症的评分，特别是LMR和NLR，在预测接受TACE治疗的中期HCC患者的治疗反应和短期预后方面的价值。未来的研究应侧重于验证这些评分的临床适用性，并评估其对患者长期生存和治疗决策的影响。
肿瘤(癌症)患者之家